Marker Therapeutics, Inc. (MRKR) NASDAQ
1.45
+0.03(+2.11%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.45
+0.03(+2.11%)
Currency In USD
| Previous Close | 1.42 |
| Open | 1.44 |
| Day High | 1.46 |
| Day Low | 1.44 |
| 52-Week High | 4.07 |
| 52-Week Low | 0.81 |
| Volume | 23,302 |
| Average Volume | 107,998 |
| Market Cap | 15.66M |
| PE | -2.64 |
| EPS | -0.55 |
| Moving Average 50 Days | 1.46 |
| Moving Average 200 Days | 1.32 |
| Change | 0.03 |
Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 18, 2026 1:00 PM GMT
HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and so
Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology
GlobeNewswire Inc.
Jan 26, 2026 12:00 PM GMT
National broadcast highlights the need for new approaches in one of the deadliest forms of cancerHOUSTON, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company with the worldwide exclus
Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer
GlobeNewswire Inc.
Jan 05, 2026 12:00 PM GMT
Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with pancreatic cancer in Arm A of the clinical study Study highlights correlation between the clinical benefit an